Coagulation activation is associated with interleukin-6 plasma levels in patients with mechanical prosthetic heart valves

In Vivo

Volumn 20, Issue 3, 2006, Pages 427-430

  Liebe, Volker ^a   Kaden, Jens J ^a   Isaac, Sanjay ^a   Brueckmann, Martina ^a   Hoffmann, Ursula ^a   Bertsch, Thomas ^b   Borggrefe, Martin ^a   Dempfle, Carl Erik ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

Author keywords

Anticoagulant therapy; Fibrin degradation products; Inflammation; Prosthetic heart valve

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; INTERLEUKIN 6;

ADULT; AGE DISTRIBUTION; AGED; ANTICOAGULATION; AORTA VALVE STENOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; POSTOPERATIVE INFLAMMATION; PROTEIN BLOOD LEVEL; RISK FACTOR; SENSITIVITY ANALYSIS; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; THROMBOSIS PREVENTION;

EID: 33646848557     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Stein PD, Alpert JS, Bussey HI, Dalen JE and Turpie AG: Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 119(1 Suppl): 220S-227S, 2001.
2. Vene N, Mavri A, Košmelj K and Stegnar M: High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 90: 1163-1172, 2003.
3. Matsuo T, Kobayashi H, Kario K and Suzuki S: Fibrin D-dimer in thrombogenic disorders. Semin Thromb Hemost 26: 101-107, 2000.
4. Giansante C, Fiotti N, Calabrese S et al: D-dimer and anticoagulation in patients with mechanical prosthetic heart valves. Arterioscler Thromb Vasc Biol 17: 1320-1324, 1997.
5. Nazli C, Kinay O, Tunc B et al: Diagnostic value of D-dimer and antithrombin-III levels in predicting prosthetic heart valve thrombosis. Tex Heart Inst J 30: 268-279, 2003.
6. Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A and Aarden L: Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 160: 5130-5135, 1998.
7. Robson SC, Shephard EG and Kirsch RE: Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 86: 322-326, 1994.
8. Stouthard JML, Levi M, Hack CE et al: Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 76: 738-742, 1996.
9. Harris TB, Ferrucci L, Tracy RP et al: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106: 506-512, 1999.
10. O'Malley T, Ludlam CA, Riemermsa RA and Fox KA: Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1). Potential risk factor for the acute coronary syndromes. Eur Heart J 22: 1226-1234, 2001.
11. Sahn DJ, DeMaria A, Kisslo J and Weyman A: Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58: 1072-1083, 1978.
12. Kerr R, Stirling D and Ludlam CA: Interleukin 6 and haemostasis. Br J Haematol 115: 3-12, 2001.
13. Ridker PM, Hennekens CH, Cerskus A and Stampfer MJ: Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 90: 2236-2240, 1994.
14. Fowkes FG, Lowe GD, Housley E et al: Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 342: 84-85, 1993.
15. Cushman M, Folsom AR, Wang L et al: Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood 101: 1243-1248, 2003.
16. Mestries JC, Kruithof EKO, Gascon MP, Herodin F, Agay D and Ythier A: In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons. Eur Cytokine Netw 5: 275-281, 1994.
17. Roldán V, Marín F, Blann AD et al: Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 24: 1373-1380, 2003.
18. Kamath SK, Blann AD, Chin BSP and Lip GYH: A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol 40: 484-490, 2002.